Clinical Trial Update: STI571 Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating the combination of STI571 (imatinib) with cytarabine in patients with chronic myeloid leukemia, including blast phase and …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Blast Phase Chronic Myeloid Leukemia
• Chronic Myeloid Leukemia

Drugs mentioned

• CYTARABINE (CYTARABINE)
• STI571 (imatinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Blastic Phase Chronic Myelogenous Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Phase 1, Phase 2 | Status: COMPLETED